• +1-646-491-9876
    • +91-20-67278686

    Search

    Female Sexual Dysfunction Pipeline Review H1 2017

    Female Sexual Dysfunction Pipeline Review H1 2017

    • Report Code ID: RW0001866801
    • Category Pharmaceuticals
    • No. of Pages 74
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Female Sexual Dysfunction - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2017, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

    Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 1, 2, 8, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health) .
    - The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Female Sexual Dysfunction - Overview
    Female Sexual Dysfunction - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Female Sexual Dysfunction - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Female Sexual Dysfunction - Companies Involved in Therapeutics Development
    Allergan Plc
    Emotional Brain BV
    Fabre-Kramer Pharmaceuticals Inc
    GlaxoSmithKline Plc
    M et P Pharma AG
    M Pharmaceutical Inc
    Palatin Technologies Inc
    Re-Pharm Ltd
    Strategic Science & Technologies LLC
    TherapeuticsMD Inc
    Valeant Pharmaceuticals International Inc
    Female Sexual Dysfunction - Drug Profiles
    (buspirone hydrochloride + testosterone) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (sildenafil citrate + testosterone) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AB-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BP-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bremelanotide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    estradiol acetate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Extrinsa - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FKW-00GA - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    gepirone hydrochloride ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S1B-3006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    S1B-307 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sildenafil citrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SIP-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Sexual Dysfunction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Dopamine D2 Receptor for Sexual Dysfunction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPT-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBS-2 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    WC-3011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Female Sexual Dysfunction - Dormant Projects
    Female Sexual Dysfunction - Discontinued Products
    Female Sexual Dysfunction - Product Development Milestones
    Featured News & Press Releases
    Jun 06, 2017: M Pharmaceutical Receives USPTO Trademark Protection for Extrinsa for the Treatment of Female Sexual Dysfunction
    Mar 20, 2017: Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
    Feb 27, 2017: AMAG and Palatin Announce Rekynda Data Presentations at the International Society for the Study of Women's Sexual Health Annual Meeting
    Nov 01, 2016: Bremelanotide Meets Co-Primary Endpoints in Palatins Phase 3 Trials for Hypoactive Sexual Desire Disorder
    Sep 23, 2016: Palatin Technologies Presents Bremelanotide Neurobiology and Treatment Efficacy Review at World Meeting on Sexual Medicine
    Aug 04, 2016: Palatin Technologies Announces Completion of All Patient Visits In Phase 3 Clinical Trials of Bremelanotide for Hypoactive Sexual Desire Disorder
    Jun 30, 2016: Catalent Announces Agreement To Commercially Supply Palatin Technologies' New Bremelanotide Female Sexual Dysfunction Product In Pen Injectors
    Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting
    Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction
    Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction
    Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference
    Oct 28, 2015: Strategic Science and Technologies Initiates Phase 2 Study to Evaluate Topical Sildenafil in Women with Female Sexual Arousal Disorder
    Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Female Sexual Dysfunction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Female Sexual Dysfunction - Pipeline by Allergan Plc, H1 2017
    Female Sexual Dysfunction - Pipeline by Emotional Brain BV, H1 2017
    Female Sexual Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2017
    Female Sexual Dysfunction - Pipeline by GlaxoSmithKline Plc, H1 2017
    Female Sexual Dysfunction - Pipeline by M et P Pharma AG, H1 2017
    Female Sexual Dysfunction - Pipeline by M Pharmaceutical Inc, H1 2017
    Female Sexual Dysfunction - Pipeline by Palatin Technologies Inc, H1 2017
    Female Sexual Dysfunction - Pipeline by Re-Pharm Ltd, H1 2017
    Female Sexual Dysfunction - Pipeline by Strategic Science & Technologies LLC, H1 2017
    Female Sexual Dysfunction - Pipeline by TherapeuticsMD Inc, H1 2017
    Female Sexual Dysfunction - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
    Female Sexual Dysfunction - Dormant Projects, H1 2017
    Female Sexual Dysfunction - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Female Sexual Dysfunction - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Female Sexual Dysfunction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Emotional Brain BV
    Fabre-Kramer Pharmaceuticals Inc
    GlaxoSmithKline Plc
    M et P Pharma AG
    M Pharmaceutical Inc
    Palatin Technologies Inc
    Re-Pharm Ltd
    Strategic Science & Technologies LLC
    TherapeuticsMD Inc
    Valeant Pharmaceuticals International Inc

    Request for Sample

    Report Url http://www.reportsweb.com//female-sexual-dysfunction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//female-sexual-dysfunction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//female-sexual-dysfunction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments